1
Objective. Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (JIA) and has pathologic similarity to hemophagocytic lymphohistiocytosis (HLH). Intronic variants in UNC13D are found in patients with familial HLH type 3 (FHLH3), but the role of noncoding variants in MAS is unknown. The objective of this study was to identify deep intronic UNC13D variants in patients with MAS.
Methods. A custom enrichment library was constructed to sequence a genomic region of~1 Mb flanking UNC13D in 24 patients with systemic JIA, recurrent MAS, and negative results of prior genetic (exon/coding) testing. The functional consequences of intronic variants were assessed using quantitative polymerase chain reaction in patient-derived peripheral blood mononuclear cells (PBMCs), electromobility shift assay, in vitro transcriptional enhancer assays, and natural killer (NK) cell degranulation assays.
Results. We evaluated a patient with systemic JIA and recurrent MAS in whom a novel functional intronic variant in UNC13D, c.117+143A>G, was observed. This variant occurred in a proposed regulatory region that drives lymphocyte-specific UNC13D expression and is associated with reduced transcript levels in patient PBMCs. This variant also disrupted NF-jB binding to a functional transcriptional enhancer, leading to reduced enhancer activity in vitro. Partial knockdown of UNC13D expression also led to impaired NK cell degranulation. An additional patient was identified with a previously described UNC13D intronic variant, for a total noncoding variant hit rate of 8.3% (2 of 24).
Conclusion. These findings highlight the notion that intronic variants in key regulatory regions may be associated with MAS in patients with systemic JIA and support deep sequencing approaches when causative coding variants are not identified.
Macrophage activation syndrome (MAS) is a lifethreatening episode of hyperinflammation that is characterized clinically by cytopenia, liver dysfunction, coagulopathy, and a systemic "cytokine storm." Although MAS has been reported to occur in numerous rheumatic diseases, in pediatric rheumatic diseases it is most often a complication of systemic juvenile idiopathic arthritis (JIA), a severe and distinct subtype of childhood-onset chronic arthritis (1) . MAS bears striking similarity to the rare histiocytic disorder hemophagocytic lymphohistiocytosis (HLH), in which genetic defects in the perforin exocytosis pathway lead to profoundly depressed cytolytic activity of natural killer (NK) cells and CD8 T cells (2) . Increasingly, hypomorphic protein-altering variants in these genes have been reported in patients with MAS, including MUNC13-4 (encoded by UNC13D), which mediates fusion of perforin-containing lytic granules with the plasma membrane, and a deficiency of which causes familial HLH type 3 (FHLH3) (2) (3) (4) . Deep intronic variants in UNC13D have also been identified in HLH patients from Europe and North America (5-7). These variants frequently involve the first intron of UNC13D, which appears to serve as a key regulatory region, and 1 variant, c.118-308C>T, has been shown to disrupt transcription factor binding to a cytotoxic lymphocyte-specific alternative promotor, thereby selectively diminishing UNC13D expression in cytolytic cells (8) . However, the presence of intronic or noncoding variants in MAS has been largely unexplored.
Herein, we describe a previously healthy 13-monthold white male with systemic JIA who later developed recurrent episodes of MAS despite receiving traditionally effective treatment. Although testing for coding variants in HLH-associated genes was not revealing, the patient was found to have a novel UNC13D variant in the lymphocytespecific intronic promotor. In support of a causative role for this variant, reduced levels of the alternative, lymphocyte-specific transcript were observed in the patient's peripheral blood mononuclear cells (PBMCs). Finally, we further show that this variant disrupts an NF-jB site that functions as a transcriptional enhancer in vitro, potentially resulting in decreased UNC13D expression and compromised natural killer (NK) cell degranulation.
PATIENTS AND METHODS
Patient data and study approval. This study was approved by the Cincinnati Children's Hospital Institutional Review Board (no. 2011-1517), and informed consent was obtained from all patients and/or their legal guardians. Data pertaining to our patient's clinical course, laboratory values, and treatment were collected from the electronic medical records. Whole blood was obtained using sodium heparin as an anticoagulant. PBMCs were separated by Ficoll density-gradient centrifugation, and RNA was extracted using TRIzol, as previously described (9) . When indicated, PBMCs were treated with recombinant human tumor necrosis factor (TNF) (Thermo Fisher) for 6 hours prior to RNA extraction.
UNC13D sequencing. In order to examine possible intronic variants, a custom enrichment library was constructed using a SeqCap EZ system (NimbleGen) to sequence a genomic region of 1 Mb on chromosome 17 (Human Genome hg19 start site 73,448,832 and stop site 74,504,525) that flanks UNC13D. The design specification showed that 98% of the targeted region overlapped with specific probes. Patient DNA was enriched for the target genomic region using a solution-based SeqCap EZ library with 2 million probes for the custom target. A cohort of 24 patients with recurrent systemic JIA-associated MAS or secondary HLH who had prior negative results of genetic exonic testing were sequenced in 2 runs, using Illumina HiSeq 2000 (paired-end design) and a large library (average size 600 bp) to ensure coverage of Alu sequence regions. Sequence reads were filtered first by quality measurement and then matched to the reference sequence of human genome (hg 19). Next, variants were annotated using NextGENe software version 2.3.4 (SoftGenetics LLC). Variants were filtered based on the frequency in dbSNP and the ExAC database and then examined with respect to phyloP scores for nucleotide conservation and overlap with transcription factor binding motifs from ChIP-Seq data. Additionally, variants were assessed based on manually curating the motif score to remove lower similarity sites, and visual inspection of the quality sequence was used to remove common artifacts known in repetitive regions. Transcription factors for specific reference and mutant nucleotide sequences were matched via the TransFac database.
Real-time reverse transcription-polymerase chain reaction (RT-PCR). RNA extraction and complementary DNA (cDNA) synthesis were performed as previously described (9) . Real-time PCR was performed using a ViiA 7 Real-Time PCR system with gene-specific primers and SYBR Green Supermix (Thermo Fisher). Message copy numbers were normalized against the copy number of the housekeeping gene, GAPDH. The primers for GAPDH (9) and the conventional and intron 1 transcripts of UNC13D (8) were described previously.
Electrophoretic mobility shift assay (EMSA). An EMSA was performed using a mixture of nuclear extracts from activated NK-92 cells and IRDye 700-labeled NF-jB consensus oligonucleotides, as previously described (10) . The wild-type (WT) oligonucleotide probe sequence for the NF-jB-like enhancer (143A) located within UNC13D intron 1 was ACCCTGGGGA-GAGCCCCCTGGG. The mutant-type oligonucleotide probe sequence for the NF-jB-like enhancer (143G) included in UNC13D intron 1 was ACCCTGGGGAGGGCCCCCTGGG.
Enhancer assay. The WT or mutant NF-jB-like enhancer (143 A/G; 3xTGGGGAG[A/G]GCCCCCT) was inserted into the enhancer site of the immediate early cytomegalovirus (CMV) promotor or HIV-1 long terminal repeat (LTR)-driven green fluorescent protein (GFP) reporter plasmid previously generated (10) to create the CMV-143A/G-GRP or the HIV-143A/G-GFP constructs. These reporter plasmids were transfected into NK-92 cells by nucleofection, as previously described (10) . The cells were rested for 24 hours and then stimulated with irradiated K562 cells (dead) for 1 hour (NK-92 cell-to-K562 cell ratio 2:1) prior to measuring GFP expression levels by flow cytometry, as previously described (11) . To further exclude the potential influence of artificially repeated core sequences, a short genomic DNA sequence (111 nt) as shown below, including the NF-jB-like WT or mutant sequence enhancer core DNA, was synthesized and inserted into the HIV-1 LTR-driven GFP reporter plasmid in either forward or reverse orientation to generate HIV-143A/G111nt-F/R-GFP plasmids. NK-92 cells were transfected with the GFP reporter plasmids and activated, and GFP was measured by flow cytometry as described above (short genomic DNA sequence of 111 nucleotides in length
. UNC13D knockdown and degranulation assays. A TriFECTa RNAi kit was purchased from IDT Inc. Transfection of NK-92 cells was performed using a 4D-Nucleofector system (Amaxa). Specifically, 4 9 10 6 cells mixed with small interfering RNA (siRNA) were suspended with 100 ll of nucleofector solution, and transfection was performed immediately using an optimally preset program. Transfected cells were cultured for 24 hours. For the degranulation assay, transfected cells were stimulated with K562 target cells (effector-to-target ratio 1:1) for 1-2 hours in the presence of phycocyanin-conjugated anti-CD107a antibody (BioLegend). This was quickly followed by flow cytometric analysis, as 964 SCHULERT ET AL described above. To detect UNC13D messenger RNA (mRNA) expression levels, total RNA was extracted from transfected NK-92 cells and reverse transcribed into cDNA using a SuperScript III First Strand Kit from Invitrogen. Real-time PCR was performed with a Bio-Rad CFX system. The housekeeping gene B2M mRNA was used for normalization, and scrambled siRNA was used for the control of UNC13D-specific siRNA. All oligonucleotides used in these experiments are shown in Supplementary 
RESULTS
We evaluated a previously healthy 13-month-old white male with daily fever for 1 month, intermittent rash, and difficulties with crawling. His parents reported that he would be very irritable for~1-2 hours upon awakening and then would improve over the course of the day. He was born at term and had no perinatal complications and no significant family medical history or environmental exposure history. His initial examination revealed mild hepatomegaly but no splenomegaly, diffuse salmon-colored rash, and polyarthritis involving the right wrist, bilateral elbows and knees, and left ankle. His initial laboratory evaluation was notable for an elevated white blood cell count of 32.1 9 10 3 /ll, a hemoglobin concentration of 11.0 gm/dl, an erythrocyte sedimentation rate of 56 mm/hour, a C-reactive protein level of 11.0 mg/dl, and the absence of autoantibodies. Systemic JIA was diagnosed, and the patient was treated with prednisone, with the addition of methotrexate and then intermittent pulse doses of methylprednisolone for refractory polyarthritis.
Approximately 4 months after diagnosis, the patient deteriorated dramatically after developing an Epstein-Barr virus infection, with persistent fevers, rash, active arthritis, and liver and spleen enlargement. His laboratory findings included white blood cell count 17.5 9 10 3 /ll, hemoglobin concentration 7.0 gm/dl, platelet count 62 9 10 3 /ll, ferritin level 1,904 ng/ml, decreasing erythrocyte sedimentation rate (to 6 mm/hour), aspartate transaminase concentration 140 units/liter, fibrinogen level 246 mg/dl, and D-dimer concentration 10.87 gm/ml. In addition, the level of soluble interleukin-1 receptor a (IL-2Ra; CD25) was elevated to 30,152 pg/ml, and the level of soluble CD163 was elevated to 80,182 ng/ml. No functional testing of cytolytic or NK cells was performed at this time. He also underwent a bone marrow biopsy, which showed hemophagocytosis. He was given a clinical diagnosis of MAS, having met 5 of 8 HLH-2004 diagnostic criteria (12) and would have satisfied the 2016 classification criteria for MAS complicating systemic JIA (13) . He was treated with intravenous methylprednisolone and cyclosporin A as well as the recombinant human IL-1R antagonist anakinra (1) , which led to a full recovery. However, while the patient was being weaned from steroids, he experienced a flare of MAS, with elevated transaminase levels and markedly elevated soluble CD25 levels. This was again controlled with methylprednisolone and increased dosing of cyclosporin A.
Because the patient had experienced recurrent episodes of MAS at an early age, he underwent genetic testing for possible HLH gene mutations, including PRF1, UNC13D, STX11, and STXBP2, but no variants were found in all coding exons and exon-intron boundaries. Because mutations in UNC13D are relatively common in patients with systemic JIA and MAS in North America (3), a more in-depth exploration of UNC13D was undertaken. In order to examine possible intronic variants, a custom enrichment library was constructed to sequence a genomic region of~1 Mb on chromosome 17 that flanked UNC13D. This array was used to sequence DNA from our patient in a batch of samples from 24 patients with recurrent systemic JIA-associated MAS or secondary HLH who had prior negative results of exonic genetic testing. For our patient, 33 million reads were generated, of which 90% passed sequence quality filtering, and 67% of quality reads were matched to the target region. The average coverage depth was 2,122, and the target region coverage depths at 109, 309, and 1009 were 95%, 94%, and 92%, respectively (complete coverage statistics for all 24 patients are shown in Supplementary Figure 1A) . Unfortunately, DNA samples from parents were not available for analysis to determine whether this variant was de novo or inherited. This variant was not present in 1000 Genomes, was present in only 1 of >30,000 alleles sequenced through gnomAD, and was not identified in any of the 23 additional sequenced patients with systemic JIA and MAS, although one of these patients did have the previously reported c.118-308C>T intronic variant, as described below and shown in Figure 1A .
Notably, there is substantial evidence that this intronic region has key roles in regulating UNC13D expression. First, there are reported H3K27Ac marks typical of transcriptional promoters on 7 unique cell lines, DNase I hypersensitivity clusters suggesting transcriptional activity in 125 cell types, and at least 15 transcription factor-binding motif overlaps in ChIP-Seq ( Figure 1A) . Second, the identified novel c.117+143A>G variant specifically overlaps with and alters a predicted consensus NF-jB transcription factor binding site ( Figure 1A HLH (6,7) . Indeed, the c.118-308C>T variant was also found in the heterozygous state in one of the 24 patients sequenced (patient 10). In addition, patient 10 was also found to have a previously reported 253-kb inversion that straddles the last 2 exons of UNC13D and has been shown to be linked to FHL3 in both northern European and North American patients (5, 6) . No other rare coding or noncoding variants (minor allele frequency <1%) were identified in UNC13D in any of the 24 patients.
Interestingly, the previously identified c.118-308C>T variant has been shown to markedly reduce UNC13D expression selectively in lymphocytes, including CD8 T cells, by disrupting transcription factor binding to an alternative promoter specifically active in cytolytic cells (6, 8) . This promoter leads to production of a second, distinct UNC13D transcript that is preferentially expressed in cytotoxic T lymphocytes and NK cells. PBMCs from our patient were not available to permit cell type-specific transcript analysis. However, total RNA previously isolated from PBMCs during a period of inactive disease was used to determine Boxed area shows consensus transcription factor binding sites that are disrupted by these changes. B, Levels of conventional and lymphocytespecific alternative UNC13D transcripts in the patient compared with the levels in 4 healthy control subjects, as determined by quantitative reverse transcription-polymerase chain reaction. Total RNA was extracted from unstimulated peripheral blood mononuclear cells (PBMCs) obtained from the patient during a period of inactive disease. Each data point represents an individual subject. Bars show the mean AE SEM. C, Levels of conventional and lymphocyte-specific alternative UNC13D transcripts in control PBMCs after treatment with tumor necrosis factor (TNF), as determined by quantitative reverse transcription-polymerase chain reaction. Bars show the mean AE SEM. Data in B and C were normalized to GAPDH to obtain the relative expression. Chr. = chromosome; RefSeq = reference sequence; HUVEC = human umbilical vein endothelial cell. * = P < 0.05 vs. untreated samples.
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SCHULERT ET AL UNC13D mRNA levels using real-time RT-PCR analysis, as previously described (8) . This demonstrated reduced levels of the alternative, lymphocyte-specific intron 1 UNC13D transcript compared with PBMCs from healthy age-matched controls, despite normal levels of the conventional UNC13D transcript ( Figure 1B) , suggesting that the novel c.117+143A>G variant may impair expression of lymphocyte-specific UNC13D transcript. Of note, the sample from our patient was obtained during a period of inactive disease; because the alternative promotor contains a putative NF-jB binding site, it is reasonable to speculate that transcript expression may increase during periods of active systemic inflammation. To examine this, PBMCs from healthy control subjects were stimulated with TNF for 6 hours, and expression of UNC13D transcripts was quantified. Treatment with TNF led to a significant and dose-dependent increase in the expression of the alternative intron 1 transcript, without significant change in the expression of the conventional transcript ( Figure 1C) .
To further characterize the functional role of this intronic region, we examined the predicted NF-jB binding site that is altered by the c.117+143A>G variant. EMSAs were performed using a consensus NF-jB oligonucleotide probe and nuclear extracts from the human NK cell line, NK-92. Two delayed bands were identified, the upper of which could be supershifted by anti-NF-jB p65 antibody (Figure 2 ). The lower band migrates consistent with NF-jB p50 (10) . Binding of nuclear extracts to the consensus NFjB oligonucleotide (both p50 and p65 bands) was largely disrupted by either unlabeled self competitor or by a 22-mer probe corresponding to the WT UNC13D intron 1 region containing the predicted NF-jB motif binding (Figure 2) . Notably, a competitor oligonucleotide containing the c.117+143A>G variant was less efficient at blocking formation of the NF-jB bands, thus confirming the notion that this variant is less efficient at disrupting NF-jB binding.
The deep intronic location of this NF-jB motif suggested that this genomic region could function as a transcriptional enhancer that can regulate gene expression from a distance independent of position and orientation. To determine whether this intronic region can serve as a transcriptional enhancer, a trimerized 15-mer sequence containing either the WT intronic sequence or the c.117+143A>G variant was cloned into the enhancer site of the immediate early CMV promoter or the HIV-1 LTR-driven GFP reporter plasmid and transfected into NK-92 cells (Figure 3A) . Cloning of the WT (143A) trimerized 15-mer sequence into either vector enhanced GFP expression in activated NK-92 cells (Figures 3B and C) . In contrast, the patient variant (143G) showed significantly reduced effect compared with the WT sequence for enhancing GFP expression driven by promoters of either CMV or HIV-1 ( Figures 3B and C) .
To confirm this further and eliminate the potential influence of artificially repeating the core sequence, a 111-nt genomic DNA region including either the WT or mutant core NF-jB enhancer was inserted into the HIV-1 vector. As shown in Figures 3D and E , the short genomic DNA containing the WT enhancer significantly increased HIV-1 LTR-driven GFP expression in activated NK-92 cells, and the mutant enhancer significantly attenuated this activity. Notably, cloning of the short genomic sequence, in either the forward or reverse orientation, significantly increased GFP expression driven by the HIV-1 LTR, further demonstrating that this region can serve as a transcriptional enhancer in vitro (Figures 3D and E) . Collectively, these results suggest that the c.117+143A>G variant alters the ability of NF-jB to bind to a transcriptional enhancer element and supports the finding of reduced alternative transcript levels in PBMCs from our patient. Figure 2 . The mutant NF-jB-like enhancer located within the UNC13D intron partially disrupts protein binding to a consensus NFjB probe. Electrophoretic mobility shift assay was performed using a mixture of nuclear extracts from activated NK-92 cells and IRDye-700-labeled NF-jB consensus oligonucleotide probe. The binding band was either supershifted by anti-p65 antibody or blocked by self, wild-type (143A), or mutant (143G) oligonucleotide competitors. The band intensities were analyzed using ImageJ (v1.50I). Values shown below the third through fifth lanes are relative to the respective noncompeted bands (second lane) (set at 1.0).
UNC13D INTRONIC VARIANT AND MAS
Taken together, these results support a model in which the c.117+143A>G variant leads to reduced lymphocyte UNC13D expression, causing diminished target cell killing. In order to examine whether a partial reduction in UNC13D expression could compromise NK cell function, UNC13D transcript was knocked down using siRNA in the human NK-92 cell line. NK-92 cells transfected with scrambled sequence or specific UNC13D siRNA were incubated with K562 target cells for 1-2 hours, and NK cell degranulation was determined by CD107a cell surface staining. Figure 2 ). These findings demonstrate that even partial reductions in UNC13D expression can compromise cytolytic cell function and further support roles for hypomorphic noncoding mutations such as c.117+143A>G in the pathogenesis of MAS.
DISCUSSION
The genetic basis of MAS in patients with systemic JIA remains unclear. However, contemporary studies have shown that as many as one-third of patients with MAS associated with systemic JIA have rare, protein-altering variants in genes associated with HLH (3, 14) . Recent work by our group and other investigators has shown that these variants can impair lymphocyte function and may explain in part the increased risk for MAS in these patients (11, 15) . In addition, whole-exome sequencing in patients with systemic JIA and MAS has identified novel candidate genes that could be implicated in this process, including several that interact with known components of the cytolytic pathway (3) .
Taken together, these findings suggest that hypomorphic variants in HLH-associated genes involved in the perforin cytolytic pathway may serve as risk factors for MAS, although this remains to be formally tested in a prospective manner. However, many patients, even those with recurrent MAS, lack any protein-altering variants in known or putative genes linked to cytolytic dysfunction. Noncoding regulatory genomic regions often are not examined, in either targeted gene sequencing or whole-exome sequencing. However, there is increasing evidence that intronic variants are significant contributors to human disease. Variants in the first intron of UNC13D, for example, are frequently identified in patients with FHLH3. The first of these to be described was c.118-308C>T, which causes a lymphocyte-specific loss of UNC13D expression due to disrupted transcription factor binding (6, 8) . In addition, the neighboring c.118-307G>A variant is associated with diminished UNC13D expression and impaired cytolytic cell degranulation (7). Thus, in our large North American cohort of >1,700 HLH patients, 79 were found to have FHLH3 (biallelic UNC13D), and more than 31% carried at least 1 noncoding mutation (5) .
Here, we describe a patient with systemic JIA and recurrent MAS who was found to have a novel UNC13D intronic variant c.117+143A>G that alters an NF-jB engagement and transcription enhancer element. Several lines of evidence support the notion that this variant impacts UNC13D expression in cytolytic cells. First, this intronic region includes H3K27Ac marks, DNase I hypersensitivity clusters, and at least 15 transcription factor binding motif overlaps from ChIP-seq data ( Figure 1A) . Second, PBMCs from this patient showed a 40% reduction in levels of the alternative, lymphocyte-specific intron 1 UNC13D transcript compared with control samples ( Figure 1B) . Of note, transcript levels were quantified in samples obtained from patients during a period of inactive disease; more profound reductions in message levels could occur during periods of hyperinflammation. Indeed, we observed that TNF stimulation of control PBMCs led to a significant increase in expression of the alternative intron 1 transcript ( Figure 1C ).
These findings are consistent with previously reported data on other intron 1 variants, most notably c.118-308C>T, which was shown to disrupt binding of the Ets family transcription factor Elf-1 (5-7) leading to lymphocyte-specific loss of UNC13D expression and defective cytolytic cell degranulation. We cannot discount the possibility that the c.117+143A>G variant may also impact transcript splicing, thereby also impacting conventional UNC13D transcript expression. Third, this variant disrupts the consensus sequence of an NF-jB binding site ( Figure 1A) , and indeed we show that the variant sequence is less efficient at blocking NF-jB bands in EMSA (Figure 2 ). Finally, this sequence serves as a transcriptional enhancer in vitro, and the c.117+143A>G variant showed significantly reduced transcriptional enhancement (Figure 3 ). Taken together, these findings strongly support the notion that the novel c.117+143A>G mutation is a functional intronic variant that diminishes lymphocyte-specific UNC13D expression.
Substantial evidence supports the notion that even partially reduced lymphocyte UNC13D expression would have functional consequences. Patients with previously described intron 1 variants displayed both reduced lymphocyte-specific UNC13D expression and impaired cytolytic function (6) (7) (8) , and UNC13D expression strongly correlated with degranulation and cytotoxicity (8) . Consistent with this, previous work by our group has shown that even partial defects in the interaction of MUNC13-4 with the effector Rab27a (~50% diminished) resulted in decreased cytolytic activity, delayed granule polarization, and increased interferon-c production resulting from prolonged engagement with target cells (11) . Finally, and most importantly, in the current study we show that partial knockdown of UNC13D message levels with targeted siRNA leads to corresponding partial defects in NK cell degranulation (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40438/abstract). This supports a model in which variants such as c.117+143A>G reduce UNC13D transcript levels, causing partial defects in cytolytic function and lowering the threshold for MAS development, particularly in patients with underlying inflammation, such as those with systemic JIA (4, 16) .
To the best of our knowledge, this is the first report of functional intronic variants associated with MAS in children with systemic JIA. Of note, we also identified the known variant c.118-308C>T in heterozygous form in an additional patient with secondary HLH/MAS (patient 10). This rare variant is present in <0.02% of the genomes listed in gnomAD but is reported in up to 9% of alleles in patients with FHLH3 (5). Extensive functional study of this variant has demonstrated that it disrupts binding of the Ets family transcription factor Elf-1, impairing recruitment of STAT-4 and diminishing chromatin remodeling (8) . Interestingly, Elf-1 can cooperate with NF-jB to activate transcription (17) , which could suggest that the biologic consequences of these 2 intronic variants are linked. Thus, together with the novel c.117+143A>G variant identified herein, the total hit rate for potentially deleterious UNC13D intronic variants in the current study was 8.3% (2 of 24).
Taken together, the findings in these patients suggest that intronic variants in key conserved regulatory regions should be examined in children with systemic JIA and MAS, and that genetic screening for variants in UNC13D should be expanded to include intron 1. Along with hypomorphic coding variants in HLH-associated genes, these intronic variants may serve as further risk factors for MAS in patients with systemic JIA and could have implications for genetic counseling. The current study further supports the utility of targeted sequencing approaches or even whole-genome sequencing in cases in which causative protein-altering mutations are not identified and provides evidence for cell-specific effects of intronic variants on transcript expression.
